Actovegin - instructions for use, dose, side effects, contraindications

Core: active substance: blood components: deproteinized hemoderivat of calves' blood - 200.0 mg in the form of Actovegin® granulate * - 345.0 mg, Excipients: Magnesium stearate 2.0 mg, talc 3.0 mg, Sheath: acacia gum - 6.8 mg, glycolic mountain wax 0.1 mg, hypromellose phthalate 29.45 mg, diethyl phthalate 11.8 mg, dye quinoline yellow varnish aluminum 2.0 mg, macrogol-6000 2.95 mg, povidone-K 30 1.54 mg, sucrose 52.3 mg, talc 42.2 mg, titanium dioxide 0.86 mg.

* Actovegin® granulate contains: active substance: Components blood: deproteinized gemoderivat blood of calves - 200.0 mg, Excipients: povidone - To 90 - 10.0 mg, cellulose microcrystalline - 135.0 mg

Description:Description: round biconvex tablets, covered with a shell of a greenish-yellow color, shiny.

Pharmacotherapeutic group:Regeneration of tissue stimulant

ATX: & nbsp

Other hematological preparations

Pharmacodynamics:Antihypoxant. ACTOVEGIN® is a hemoderivat, which is obtained by dialysis and ultrafiltration (compounds with a molecular weight of less than 5,000 daltons pass through). It positively influences transport and utilization of glucose, stimulates oxygen consumption (which leads to stabilization of plasma cell membranes in ischemia and a decrease in lactate formation), thus having an antihypoxic effect that begins to appear at the latest 30 minutes after oral administration and reaches a maximum on average after 3 hours (2-6 hours).
ACTOVEGIN ® increases the concentrations of adenosine triphosphate, adenosine diphosphate, phosphocreatine, as well as amino acids - glutamate, aspartate and gamma-aminobutyric acid.
The effect of ACTOVEGIN® on the assimilation and utilization of oxygen, as well as insulin-like activity with the stimulation of transport and glucose oxidation, are significant in the treatment of diabetic polyneuropathy (DIN).
In patients with diabetes mellitus and diabetic polyneuropathy, ACTOVEGIN® reliably reduces the symptoms of polyneuropathy (stitching, burning sensation, parasthesia, numbness in the lower extremities).
Objective disorders are reduced sensitivity, mental well-being of patients improves.

Pharmacokinetics:With the help of pharmacokinetic methods it is impossible to study the pharmacokinetic indices of the drug ACTOVEGIN®, since it consists only of the physiological components that are usually present in the body.
To date, there has been no reduction in the pharmacological effect of hemoderovatives in patients with altered pharmacokinetics (eg, hepatic or renal insufficiency, metabolic changes associated with advanced age, and metabolic peculiarities in newborns).

Indications:Complex therapy of metabolic and cerebral disorders of the brain (various forms of cerebral circulatory insufficiency, dementia, craniocerebral trauma); Peripheral (arterial and venous) vascular disorders and their consequences (angiopathy, trophic ulcers); diabetic polyneuropathy.

Contraindications:Hypersensitivity to the drug ACTOVEGIN® or similar drugs.

Carefully:Heart failure of P and N degree, pulmonary edema, oliguria, anuria, hyperhydration; pregnancy, lactation.

Pregnancy and lactation:Allowed.

Dosing and Administration:Inside, 1-2 tablets 3 times a day, without chewing, before eating, squeezed a small amount of liquid. Duration of treatment should be from 4 to 6 weeks.
With diabetic polyneuropathy: 2000 mg per day intravenously for 3 weeks with the subsequent transition to the tablet form - 2-3 tablets 3 times a day for at least 4-5 months.

Side effects:Allergic reactions (eg, urticaria, swelling, drug fever). In such cases, treatment with ACTOVEGIN® should be discontinued.If necessary, a standard therapy for allergic reactions (antihistamines and / or corticosteroids) is performed.

Interaction:It is currently unknown.

Form release / dosage:The coated tablets are 200 mg.

Packaging:For 50 tablets in bottles of dark glass with a screw mouth, sealed with aluminum caps with the control of the first autopsy.
1 bottle with instruction for use is placed in a pack of cardboard. On the pack are glued transparent protective labels of a round shape with holographic inscriptions and the control of the first autopsy.
In the case of the production and / or packaging and packaging of the drug at OOO Takeda Pharmaceuticals, Russia:
For 50 tablets in bottles of dark glass with a screw mouth, sealed with aluminum caps with the control of the first autopsy.
1 bottle with instruction for use is placed in a pack of cardboard. On the pack are glued transparent protective labels of a round shape with holographic inscriptions and the control of the first autopsy.
In the case of packaging and packaging of the drug at ZAO "FarmFirma Soteks", Russia:
For 10, 30 or 50 tablets in bottles of dark glass with a screw mouth, sealed with aluminum caps with the control of the first opening.
1 bottle with instruction for use is placed in a pack of cardboard.

Storage conditions:In the dark place at a temperature of no higher than 25 ° C.
Keep out of the reach of children!

Shelf life:3 years. Do not use after expiry date.

Terms of leave from pharmacies:On prescription

Registration number:П N014635 / 03

Date of registration:19.12.2007 / 29.02.2016

Expiration Date:Unlimited

The owner of the registration certificate:Takeda Pharmaceuticals, LLCTakeda Pharmaceuticals, LLC Russia

Manufacturer: & nbsp

TAKEDA, GmbH Germany

GLOBOPHARM Pharmazeutische Produktions- und Handelsgesellschaft, mbH Austria

Takeda Pharmaceuticals, LLC Russia

Representation: & nbspTakeda Pharmaceuticals Ltd.Takeda Pharmaceuticals Ltd.

Information update date: & nbsp06.10.2016

Illustrated instructions

Instructions

Actovegin (Actovegin)